In Re Brand Name Prescription Drugs Antitrust Litigation

867 F. Supp. 1338, 1994 U.S. Dist. LEXIS 15189, 1994 WL 635031
CourtDistrict Court, N.D. Illinois
DecidedOctober 24, 1994
Docket94 C 897. No. MDL 997
StatusPublished
Cited by6 cases

This text of 867 F. Supp. 1338 (In Re Brand Name Prescription Drugs Antitrust Litigation) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Brand Name Prescription Drugs Antitrust Litigation, 867 F. Supp. 1338, 1994 U.S. Dist. LEXIS 15189, 1994 WL 635031 (N.D. Ill. 1994).

Opinion

MEMORANDUM OPINION

KOCORAS, District Judge:

This matter is before the Court on five Motions for Summary Judgment pursuant to Rule 56 of the Federal Rules of Civil Procedure.

First, the Wholesaler Defendants 1 move for Summary Judgment on plaintiffs’ claims against them in the Consolidated and Amended Complaint under § 1 of the Sherman Act, 15 U.S.C. § 1. According to the Wholesaler Defendants, the plaintiffs’ chargeback allegations find no support in either fact or law.

Next, the Manufacturer Defendants 2 move for Judgment on the Pleadings pursuant to Rule 12(c) of the Federal Rules of Civil Procedure, or in the alternative for Summary Judgment, dismissing the indirect purchaser claims asserted against them in the Consolidated and Amended Complaint. As grounds for their motion, the Manufacturer Defendants maintain that the putative class plaintiffs, as indirect purchasers, lack standing under Illinois Brick Co. v. Illinois, 431 U.S. 720, 97 S.Ct. 2061, 52 L.Ed.2d 707 (1977).

Finally, Defendant Burroughs Wellcome, Co. (“Burroughs Wellcome”) moves for Summary Judgment in its favor on certain 3 individual plaintiffs’ Sherman Act claims for treble damages under § 4 of the Clayton Act, 15 U.S.C. § 15. In support of its motion Burroughs Wellcome asserts that the plaintiffs in the various individual actions, with the exception of Plaintiff Albertson’s Inc., have not purchased brand-name prescription drugs directly from Burroughs Wellcome. Accordingly, Burroughs Wellcome claims that under Illinois Brick, the plaintiffs who are indirect purchasers are barred from recovering treble damages under § 4 of the Clayton Act. 4

Each motion will be addressed below. Before proceeding, however, we first examine the legal standard from which to judge a motion for summary judgment.

LEGAL STANDARD

Summary judgment is appropriate if the pleadings, answers to interrogatories, admis *1341 sions, affidavits and other material show “that there is no genuine issue as to any material fact and the moving party is entitled to judgment as a matter of law.” Fed. R.Civ.P. 56(c). “Only disputes over facts that might affect the outcome of the suit under the governing law will properly preclude the entry of summary judgment.” Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248, 106 S.Ct. 2505, 2510, 91 L.Ed.2d 202 (1986). The party seeking summary judgment carries the initial burden of showing that no such issue of material fact exists. The moving party may discharge this burden by “ ‘showing’ ... that there is an absence of evidence to support the nonmoving party’s case.” Celotex Corp. v. Catrett, 477 U.S. 317, 325, 106 S.Ct. 2548, 2554, 91 L.Ed.2d 265 (1986). Pursuant to Rule 56(e), when a properly supported motion for summary judgment is made, the adverse party must set forth specific facts showing that there is a genuine issue as to any material fact and that the moving party is not entitled to judgment as a matter of law. Anderson, 477 U.S. at 250, 106 S.Ct. at 2511.

In making our determination, we are to draw inferences from the record in the light most favorable to the non-moving party. We are not required, however, to draw every conceivable inference, but rather, only those that are reasonable. DeValk Lincoln Mercury, Inc. v. Ford Motor Co., 811 F.2d 326, 329 (7th Cir.1987); Bartman v. Allis-Chalmers Corp., 799 F.2d 311, 313 (7th Cir.1986), cert. denied, 479 U.S. 1092, 107 S.Ct. 1304, 94 L.Ed.2d 160 (1987). The nonmovant may not rest upon mere allegations in the pleadings or upon conclusory statements in affidavits; rather he must go beyond the pleadings and support his contentions with proper documentary evidence. Celotex, 477 U.S. at 324, 106 S.Ct. at 2553; Howland v. Kilquist, 833 F.2d 639, 642 (7th Cir.1987).

The plain language of Rule 56(e) mandates the entry of summary judgment against a party who fails to establish the existence of an element essential to that party’s case, and on which that party will bear the burden of proof at trial. Celotex, 477 U.S. at 322, 106 S.Ct. at 2552. “In such a situation there can be ‘no genuine issue as to any material fact,’ since a complete failure of proof concerning an essential element of the nonmoving party’s case necessarily renders all other facts immaterial”. Id. at 322-23, 106 S.Ct. at 2552.

It is in consideration of these principles that we examine the various motions before us.

DISCUSSION

I. The Wholesaler Defendants’ Motion for Summary Judgment

The Wholesaler Defendants move for summary judgment in their favor on the allegations asserted against them in plaintiffs’ Consolidated and Amended Complaint. According to the Wholesaler Defendants, the plaintiffs’ § 1 Sherman Act claims against them must fail as a matter of indisputable fact and law.

The Wholesaler Defendants contend that there is no triable issue on the question of whether they had conspired to “fix, raise, maintain and stabilize the prices of Prescription Brand Name Drugs sold to the plaintiffs and the [putative] class members at supra-competitive levels.” Consolidated and Amended Class Action Complaint at ¶79. As the Wholesaler Defendants see it, the plaintiffs’ conspiracy allegations, as they relate to the Wholesalers, are based only upon chargeback agreements entered into by each Wholesaler with the Manufacturer Defendants. The Wholesaler Defendants contend that as a matter of undisputable fact, the chargeback agreements 5 do not fix or restrict the prices at which the Wholesalers can sell the Manufacturers’ products to plaintiffs. Thus, argue the Wholesalers, since these chargeback agreements are legal on their face and do not directly involve the plaintiffs, the plaintiffs’ conspiracy allegations against the Wholesaler Defendants must fail. We do not agree with the Wholesaler Defendant’s approach of fragmenting and eompartmental- *1342

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Animal Science Products, Inc. v. China Minmetals Corp.
34 F. Supp. 3d 465 (D. New Jersey, 2014)
Drug Mart Pharmacy Corp. v. American Home Products Corp.
378 F. Supp. 2d 134 (E.D. New York, 2005)
Jersey Dental Laboratories v. Dentsply International, Inc.
180 F. Supp. 2d 541 (D. Delaware, 2001)
McCARTHY v. RECORDEX SERVICE, INC.
80 F.3d 842 (Third Circuit, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
867 F. Supp. 1338, 1994 U.S. Dist. LEXIS 15189, 1994 WL 635031, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-brand-name-prescription-drugs-antitrust-litigation-ilnd-1994.